Skip to content

Study · Not a test of the peptide alone · 2018

3 results

Combined teriparatide and denosumab therapy accelerates spinal fusion following posterior lumbar interbody fusion.

Ide M, Yamada K, Kaneko K, Sekiya T, Kanai K, Higashi T, Saito T

Orthopaedics & traumatology, surgery & research : OTSR1 Sept 2018Cited by 40 (Europe PMC)

PMID30179720 (opens in a new tab)DOI10.1016/j.otsr.2018.07.015 (opens in a new tab)PepBankPUB-30179720
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

  1. 01HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome

    After lumbar fusion surgery, teriparatide plus denosumab produced a smaller alkaline phosphatase increase than teriparatide alone.

    In plain wordsAfter lumbar fusion surgery, the combination produced a smaller alkaline phosphatase increase than teriparatide alone.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseAlkaline phosphatase at 3 months
    Study

    n = 16

    Comparator
    Teriparatide alone
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Alkaline phosphatase in the teriparatide group increased more than in the combination group at 3 months following surgery (p<0.05).
    2 context sentences
    Summary · context
    All patients underwent posterior lumbar interbody fusion with local bone grafts.
    Summary · context
    Sixteen osteoporotic patients with lumbar canal stenosis were randomly divided into two treatment groups

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  2. 02HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome

    After lumbar fusion surgery, teriparatide plus denosumab increased femoral neck BMD more than teriparatide alone.

    In plain wordsAfter lumbar fusion surgery, the combination increased femoral neck bone density more than teriparatide alone.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseFemoral neck BMD at 12 months
    Study

    n = 16

    Comparator
    Teriparatide alone
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Femoral neck BMD increased more in the combination group than in the teriparatide group at 12 months following surgery.
    2 context sentences
    Summary · context
    All patients underwent posterior lumbar interbody fusion with local bone grafts.
    Summary · context
    Sixteen osteoporotic patients with lumbar canal stenosis were randomly divided into two treatment groups

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  3. 03HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome

    After lumbar fusion surgery, teriparatide plus denosumab produced higher fusion rates than teriparatide alone.

    In plain wordsAfter lumbar fusion surgery, the combination produced higher fusion rates than teriparatide alone.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseFusion rate at 6 months
    Study

    n = 16

    Comparator
    Teriparatide alone
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    The combination group achieved higher fusion rates than the teriparatide group at 6 months following surgery.
    2 context sentences
    Summary · context
    All patients underwent posterior lumbar interbody fusion with local bone grafts.
    Summary · context
    Sixteen osteoporotic patients with lumbar canal stenosis were randomly divided into two treatment groups

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.